Literature DB >> 1164098

Distribution, metabolism and excretion of etomidate, a short-acting hypnotic drug, in the rat. Comparative study of (R)-(+)-(--)-Etomidate.

J J Heykants, W E Meuldermans, L J Michiels, P J Lewi, P A Janssen.   

Abstract

Tritium-labelled (R)-(+) and (S)-(--)-etomidate was injected intravenously in male Wistar rats at four dose levels. Initial plasma clearance was high and the largest part of etomidate was rapidly distributed over those tissues, that had entered in equilibrium with plasma, such as brain, erythrocytes, heart, spleen, lung, kidney, muscle and intestines. Only in subcutaneous fat, testicles and stomach peak levels appeared after 28 minutes. The levels of etomidate, observed in all these tissues varied proportionally with the dose. Although the contents in brain of thw two isomers were comparable, only (R)-(+)-etomidate possesses hypnotic activity. The concentration in brain of (R)-(+)-etomidate, producing hypnotic activity in rats, was 1.50 +/- 0.35 mug/g tissues. Peak levels in liver appeared shortly after administration. Capacity-limited ester hydrolysis in the liver was the main metabolic pathway, yielding a single amphoteric metabolite. The rate of metabolization of (R)-(+)-etomidate was higher than that of the (S)-(--)-isomer. Excretion of the metabolite was mainly with the urine.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1164098

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  10 in total

Review 1.  General anaesthetic actions on ligand-gated ion channels.

Authors:  M D Krasowski; N L Harrison
Journal:  Cell Mol Life Sci       Date:  1999-08-15       Impact factor: 9.261

2.  Contradicting a unitary theory of general anesthetic action: a history of three compounds from 1901 to 2001.

Authors:  Matthew D Krasowski
Journal:  Bull Anesth Hist       Date:  2003-07

3.  Pharmacokinetics of intravenous anaesthetics: implications for clinical use.

Authors:  M M Ghoneim; K Korttila
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

4.  Relationship between etomidate plasma concentration and EEG effect in the rat.

Authors:  P De Paepe; G Van Hoey; F M Belpaire; M T Rosseel; P A Boon; W A Buylaert
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

5.  Analogues of etomidate: modifications around etomidate's chiral carbon and the impact on in vitro and in vivo pharmacology.

Authors:  Ervin Pejo; Peter Santer; Spencer Jeffrey; Hilary Gallin; S Shaukat Husain; Douglas E Raines
Journal:  Anesthesiology       Date:  2014-08       Impact factor: 7.892

Review 6.  Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure.

Authors:  G Heinemeyer
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

7.  Kinetics of nicotinic acetylcholine ion channels in the presence of intravenous anaesthetics and induction agents.

Authors:  R E Wachtel; E S Wegrzynowicz
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

Review 8.  Clinical pharmacokinetics of the newer intravenous anaesthetic agents.

Authors:  P J Davis; D R Cook
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

9.  Electrophysiological studies of the effects of the general anaesthetic etomidate on frog myelinated nerve fibre.

Authors:  E Benoit; M R Carratù; J M Dubois; D Mitolo-Chieppa; P Preziosi
Journal:  Br J Pharmacol       Date:  1987-01       Impact factor: 8.739

10.  Development of [18F]FAMTO: A novel fluorine-18 labelled positron emission tomography (PET) radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands.

Authors:  Salvatore Bongarzone; Filippo Basagni; Teresa Sementa; Nisha Singh; Caleb Gakpetor; Vincent Faugeras; Jayanta Bordoloi; Antony D Gee
Journal:  Nucl Med Biol       Date:  2018-11-09       Impact factor: 2.408

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.